We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Feedback Plc | LSE:FDBK | London | Ordinary Share | GB00BJN59X09 | ORD 50P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 75.00 | 73.00 | 77.00 | 75.00 | 75.00 | 75.00 | 12 | 08:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Electronic Computers | 1.03M | -2.92M | -0.2188 | -3.43 | 10M |
Date | Subject | Author | Discuss |
---|---|---|---|
13/8/2021 14:41 | See that LR2. Fybberf has gone quiet too. 🤔 | ducatiman | |
13/8/2021 14:35 | Two big buys today. | lr2 | |
10/8/2021 11:28 | The technology is proven but they have got to secure the orders. I believe they will and orders could flow rapidly and then this share price will look a bargain. | gilou9 | |
10/8/2021 09:15 | On the face of it, that seems an important piece of work in the COVID saga, and the key role TEXRAD played in the process looks significant. An excellent reference from the coal face. | davwal | |
09/8/2021 22:38 | No, he doesn't. I don't really know why he's on this thread because he loves his IQAI. Bless! I just hope we get some contract announcements soon and be rid of them. Lovely day in the garden with one of my daughters and two of the grandchildren. | ged5 | |
09/8/2021 21:59 | Excellent news, LR2. I see one of Grindelwald's spikey acolytes appeared earlier. Just seen his irrelevant post on LSE. Really! | ged5 | |
09/8/2021 13:54 | I'm fine thanks Ged, just keeping quiet so I don't get into trouble telling Trevor what I really think about him. | lr2 | |
09/8/2021 13:41 | Thanks for that, Ptolemy, we do need to be reminded of being a going concern. I'm not sure I can see any similarities with FDBK though. September 2020 hadIIP £30.8m cash. Ten months later IIP have £4m cash. £26.8m in ten months equates to £2.68m per month. Not sure IIP have much more than two months cash. Certainly not at that rate. Also they renegotiated a loan not so long ago. FDBK don't have any debt and low cash burn so I'm not sure of the relevance comparing to an investment company. Anyone seen or heard from LR2? Hope he's OK. | ged5 | |
09/8/2021 12:45 | Need to face reality. IIP reporting today what happens when a Company has a precarious cash position: "As at 31 July 2021, the IIP Group had unaudited cash and cash equivalents available of $4 million, including certain cash receivables. This amounts to approximately 5-7 months of runway for the Group. The Board is currently evaluating options and is exploring alternative sources of financing with third parties and further announcements will be made as and when appropriate." Down 25%. | ptolemy | |
09/8/2021 11:41 | Looking back to March 20 the share price touched .3p about the time the Pennine Pilot study was paused. Within days the share price recovered to about 1.25p and by the end of April about 1.55p. Placing in June 20 then the share price gave some the chance to cash in in August 20 when the bid hit 2.2p. Today it's looking bad for holders but things can soon change with FDBK. The NHS will be struggling for cash with having to fund some of the recent pay rise but FDBK isn't just about the NHS.. India, veterinary and from the website:- additionally, we are beginning to explore the significant opportunities that exist in the wider consumer market. Selling now might seem a good idea if you think it will reach those lows of last year. It's up to the company to announce some contracts. Just over three weeks since the last one, so come on Tom let's have another one or three. | ged5 | |
09/8/2021 09:48 | Connect with colleagues quickly and review the information you need to reach safer decisions for your patients. Practice the way you want to, with a system that works for you. Bleepa is the only compliant communication platform that enables you to share and annotate clinical-grade images on mobile devices, giving you networked care at your fingertips. Bleepa supports clinical referrals and treatment decisions within and between hospitals, community diagnostic hubs and other care settings, helping to speed up referral times for your patients wherever they need to go. Don't forget Davwal, Bleepa is already being used by veterinary customers. Also looking forward to hearing about contracts in India. I notice the first trade of the day reported elsewhere isn't showing on the volume chart in the header. Any ideas as to why? | ged5 | |
09/8/2021 08:40 | I still think M&A is a possible curve-ball that could involve Feedback. There are too many players but some have offerings that could possibly dovetail with Bleepa. | davwal | |
09/8/2021 08:39 | Bleepa's USP is the sending of useable digital images. | orange1 | |
09/8/2021 08:31 | I'm not sure there was any lunch to begin with, but it sure looks as though Medic Bleep is or will eat Bleepa's Mittagessen if there is. "Medic Bleep is a communication app with tailored healthcare functionality that meets General Data Protection Regulation and NHS information governance standards. Features include: Individual and group text and audio messaging Audio calls Image and file sharing Patient information tab Audit trail View when a message is sent, delivered and read View role, availability and on-call status of colleagues Searchable organisation directory Pin/fingerprint protected login Mobile, tablet and computer access Broadcast messaging Business intelligence dashboard for trends and reporting" | ydderf | |
08/8/2021 21:16 | Medic Bleep boasts that its system can reach doctors who are on call instead of letting people send messages to doctors in the hope that they are on call and respond. “Medic Bleep can help you and your team realize time savings, productivity gains, and improvements to quality of care. You can reach the team when you need them most, coordinate with other departments in real time, and get patient information when you need it. The Directory and Roles features make it easy to know who’s on call without having to find a whiteboard schedule or call someone to ask.” www.medicbleep.com | orange1 | |
08/8/2021 19:40 | No idea if Bleepa could help in this situation, probably not. However it looks like the NHS is currently overwhelmed. My Sister is immune suppressed, through a very rare disease. She has IVIG regularly and retuximab when required. She could have pneumonia and not display symptoms and is on steroids. She rang 111 this morning as was feeling unwell with infection indicators. She needs antibiotics. 12.5 hours later and there is not a clinician, as yet, available to prescribe. | ducatiman | |
06/8/2021 17:55 | Ged5 5 Aug '21 - 15:00 - 8371 of 8375 0 0 0 "... Since then, there's been the veterinary contract. Now all that's needed is several more contracts to justify a higher mkt cap." How much will the veterinary contract generate on an ongoing basis? Even if you assume say a dozen Bleepas per practice, generating about £100 p.a. per Bleepa, that would only be about £24K. of revenue p.a. from that contract. And that could be optimistic. It's certainly a start, but the company would need a lot more than several of such contracts to justify a higher market cap. That said, I hope that they come, and that shareholders here benefit. | hedgehog 100 | |
05/8/2021 17:08 | That article was written by Dr Venkat Ramana Sudigali.Consultant Radiologist NHS/Ireland. MBA@ISB. Director, Excell Hospital. Ambassador of UK Royal College of Radiologists/Oncolog | ragnarr | |
05/8/2021 17:01 | Wow have we finished with a miniscule rise? Put that in your pipe and smoke it freddy. | digger2779 | |
05/8/2021 16:44 | If it comes Ged! We wouldn’t see fybberf again either 😂🧐. Here’s hoping. | ducatiman | |
05/8/2021 15:56 | "Another gap in our systems that the pandemic has highlighted, is the protection of our staff and where they are located. When the Delta variant hit, we were left scrambling. Our doctors and nurses were becoming ill themselves but without a way to work remotely, there were gaps in hospital rotas. This meant that medical staff still able to work had to work harder, travel between hospitals, and were, therefore, more likely to pass on the infection. Some were forced to provide care without the right levels of expertise as clinicians increasingly had to self-isolate. Secure clinical communications How do we begin to solve these issues? One of the many possible solutions is having a secure, medical-grade communications platform like Bleepa. This allows medical staff to review clinical-grade images and communicate on their phones and devices. They can share and annotate the images and discuss patient cases with colleagues anywhere, in an instant. Why would this help? Well firstly, if a clinician has to self-isolate, is on call, or is simply on their day off, they can very quickly help colleagues in any location with guidance or advice from their home. They don’t need to be in the hospital to do this. They can simply check their phone, make an assessment and guide their colleague in the same way they would if they were there in person. This would help to protect our medics while they are continuing with their work. Secondly, and more importantly, for the long term, it would enable clinicians not to have to travel between hospitals unless absolutely necessary. They can be located at their main employ and provide valuable insight and guidance from there. Saving them time and stress, and saving hospitals time and money on travel." | ged5 | |
05/8/2021 15:00 | Certainly correct about being overvalued based on last years revenue, which was more than £200k. Note that the eoy is 31st May. By 8th June they had invoiced £120k. So as LR2 mentioned many posts ago, that invoice was in the first 8 days of the present year. Since then, there's been the veterinary contract. Now all that's needed is several more contracts to justify a higher mkt cap. | ged5 |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions